XTalks

JANUARY 21, 2025

From non-invasive cancer diagnostics to life-saving cardiovascular implants, the latest medical devices cleared or approved by the FDA in 2024 reflect the remarkable strides in science and engineering. If parvovirus B19 antibodies are present, they bind to the chemicals and particular particles in the test, producing a light signal.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

Pharmaceutical Technology

FEBRUARY 28, 2023

Breakthroughs in therapies containing monoclonal antibodies (mAbs) are showing ever-greater potential in treating a range of diseases, alongside biopharma manufacturers facing the challenge of keeping up with demand for production while controlling costs. Increasing product yield is the most fundamental way to achieve this.

Production 237

Production Manufacturing Engineer Containment 237

XTalks

MAY 7, 2021

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first, “original” strain of SARS-CoV-2. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. It was generally well-tolerated and elicited robust antibody response in Phase I/II clinical testing.

Protein 97

Protein Vaccination Vaccine Trials 97

The Pharma Data

JANUARY 12, 2021

LONDON, UK / ACCESSWIRE / January 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company (“GlobalCo”).

Antibody 40

Antibody Development Licensing Licensing 40

Pharmaceutical Technology

MARCH 22, 2023

Monoclonal antibodies (mAbs) are one crucial area where therapeutics are providing hope for people living with severe medical conditions that currently have limited treatment options. It contains anion exchange (AEX) fibrous chromatography media for the chromatographic capture of cells, debris, and soluble impurities.

Production 130

Production Manufacturing Engineer Containment 130

XTalks

AUGUST 17, 2020

With several biologics in the pipeline, including one in early stage clinical trials for head and neck cancer, the company is positioned to engineer highly specific biologics against immune targets in the body. Monoclonal antibodies : these are antibodies that are designed to bind to specific targets on cells.

Protein 98

Protein Engineer Immune Response In-Vivo 98

The Pharma Data

AUGUST 15, 2021

Now, researchers reporting in ACS Central Science have immunized mice with nanoparticles that mimic SARS-CoV-2 by displaying multiple copies of the receptor binding domain (RBD) antigen, showing that the vaccine triggers robust antibody and T cell responses. Although the first vaccines to receive Emergency Use Authorization by the U.S.

Protein 52

Protein Vaccination Vaccine Antibody 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Antibody 40

Antibody Vaccination Vaccine Trials 40

The Pharma Data

DECEMBER 1, 2020

is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. About Innate Pharma: Innate Pharma S.A. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia.

Containment 52

Containment Antibody Production Engineer 52

The Pharma Data

DECEMBER 29, 2020

The integration of IPA’s expertise in rapidly isolating anti-virus antibody fragments from its in-house antibody libraries, coupled with the robust nanoparticle-based theranostic platform, serves as a proof-of-concept study to enable the rapid detection of future pandemic pulmonary viruses. About ImmunoPrecise Antibodies Ltd.

Antibody 52

Antibody In-Vitro Engineer Development 52

The Pharma Data

DECEMBER 16, 2020

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. Additional terms of the agreement were not disclosed. About NVX-CoV2373. and Australia.

Protein 52

Protein Vaccination Vaccine Immune Response 52

The Pharma Data

NOVEMBER 9, 2020

NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19. About NVX-CoV2373. and Australia.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Roots Analysis

FEBRUARY 15, 2022

ADCs are engineered therapeutics comprised of monoclonal antibodies attached to potent cytotoxic payloads through chemical linkers. Over time, the intellectual property related to ADC payloads / warheads has grown at a significant rate, primarily for ADCs containing auristatin, calicheamicin and maytansinoids as payloads.

Contract Manufacturing 52

Contract Manufacturing Manufacturing Marketing Containment 52

The Pharma Data

JULY 27, 2021

Acquisition Complements Amgen’s Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer. billion in cash. Reese, M.D., executive vice president of Research and Development at Amgen.

Production 52

Production Antibody Sales Development 52

The Pharma Data

OCTOBER 26, 2020

On 14 May 2018, the Company announced a collaboration with GlobalCo to work on its CDX antibody. This additional extension of the collaboration will allow us to choose the best CDX antibody for pre-clinical and clinical development.” This work complements the Company’s own development work currently being undertaken.

Development 40

Development Antibody Engineer Production 40

The Pharma Data

JANUARY 4, 2021

IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format. IPH6101/SAR443579 is a NKp46-based NK cell engager (NKCE) using Innate’s proprietary multispecific antibody format (Gauthier et al. MARSEILLE, France, Jan. MARSEILLE, France, Jan. Cell 2019 ).

Development 40

Development Antibody Drugs Containment 40

The Pharma Data

NOVEMBER 30, 2020

About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. Novavax was awarded $1.6 billion in funding from the U.S. and Australia.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

The Pharma Data

DECEMBER 8, 2020

. Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies.

Antibody 40

Antibody Engineer Containment Sales 40

The Pharma Data

DECEMBER 20, 2020

platform and its patented large-capacity VV cop TK-RR- oncolytic virus, which has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR ® /F.I.R.S.T LUND, Sweden and STRASBOURG, France , Dec. It has been generated using Transgene’s Invir.IO

Trials 40

Trials Antibody Clinical Trials Clinical Trials 40

The Pharma Data

JANUARY 18, 2021

oncolytic virus (VVcopTK-RR-), and has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T From this, BT-001 is engineered to encode both a highly differentiated Treg depleting anti-CTLA4 antibody and the human GM-CSF cytokine.

Trials 40

Trials Antibody Engineer Clinical Trials 40

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. CAMBRIDGE, Mass. , 14, 2020 /PRNewswire/ — Synlogic, Inc.

Immune Response 40

Immune Response Engineer Medicine Clinical Trials 40

The Pharma Data

OCTOBER 14, 2021

It is also approved in combination with bendamustine, followed by Gazyva/Gazyvaro maintenance for the treatment of FL patients who did not respond to a MabThera®/Rituxan® (rituximab)-containing regimen, or whose FL returned after such treatment and in combination with chemotherapy for previously untreated advanced FL.

Medicine 52

Medicine In-Vitro Antibody Genomics 52

The Pharma Data

OCTOBER 21, 2020

We are particularly excited to advance on our goal to exploit the therapeutic potential of our first in class engineered CAR ?? Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated highly potent antitumor activity in preclinical models, leading to effective long-term control of tumor growth. About Adicet.

Immune Response 40

Immune Response Engineer Clinical Trials Clinical Trials 40

The Pharma Data

MAY 7, 2021

The decision to start the rolling review is based on the interim analysis of efficacy and safety data from the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) trial, which evaluated sotrovimab as monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalisation.

Antibody 40

Antibody Trials Vaccination Vaccine 40

The Pharma Data

JANUARY 11, 2021

Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment. VIR-7832 is set to become the second monoclonal antibody from the Vir-GSK collaboration to be investigated as a potential COVID-19 treatment. SAN FRANCISCO and LONDON, Jan. George Scangos, Ph.D.,

Antibody 40

Antibody Clinical Trials Clinical Trials Trials 40

The Pharma Data

DECEMBER 8, 2020

This process is different from commonly used antibody-based processes and enables the company to overcome a key hurdle in exosome preparation, i.e. remaining antibodies in the final preparation. They contain proteins, nucleic acids and metabolites, which carry information from secreting to receiving cells.

Manufacturing 52

Manufacturing Containment Life Science Production 52

Roots Analysis

SEPTEMBER 9, 2024

The rising demand for protein therapeutics, such as monoclonal antibodies and vaccines , is driving advancements in protein expression technology to ensure efficient and scalable production. Algal Expression System: This expression system is used in genetic engineering, biofuel production, botany.

Protein 40

Protein Gene Production DNA 40

The Pharma Data

OCTOBER 22, 2020

Monalizumab may re-establish a broad anti-tumor response mediated by NK and T cells, and may enhance the cytotoxic potential of other therapeutic antibodies (André et al, Cell 2018). About Cetuximab: Cetuximab is an anti-EGFR monoclonal antibody. overall response rate, a median time to progression of 2.3

Clinical Trials 40

Clinical Trials Clinical Trials Trials Antibody 40

The Pharma Data

DECEMBER 10, 2020

The goal of targeting both S and N was to both activate virus-specific T cells and generate anti-SARS-CoV-2-neutralizing antibodies. ImmunityBio’s hAd5 vaccine generated robust neutralizing antibody activity that was present 14 days post-final vaccination. This press release features multimedia. Graphic: Business Wire).

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

JULY 6, 2021

Hemlibra is a bispecific factor IXa- and factor X-directed antibody. 12 Inhibitors are antibodies developed by the body’s immune system that bind to and block the efficacy of replacement factor VIII, 13 making it difficult, if not impossible, to obtain a level of factor VIII sufficient to control bleeding.

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 24, 2021

All participants randomized to receive either 4,200 mg of bamlanivimab, Lilly’s neutralizing antibody, or placebo. VP-102 is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidim delivered by way of a single-use applicator. Non-COVID-19-Related. BT-001 is based on the patented Invir.IO

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

JUNE 25, 2021

The CDC has defined Variant of Interest (VoI) as a variant with genetic markers that have been associated with changes to receptor binding, reduced neutralization by antibodies generated against previous infection or vaccination, or predicted increase in transmissibility or disease severity. BARDA is providing up to $1.75 About NVX-CoV2373.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

The Pharma Data

APRIL 22, 2023

Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard John A. ” Mitragotri is also the Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering at SEAS.

Immune Response 40

Immune Response Engineer In-Vivo Containment 40

The Pharma Data

NOVEMBER 11, 2020

Details of the presentation are as follows: Event: Late Breaking Developments, Part II Title: One Year and Beyond: Long-term Multiple-dose Study of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate with Extended Durability, in wAMD, DME, and RVO Presenter: Arshad M Khanani, M.D., Chief Executive Officer. About KSI-301.

Development 40

Development Antibody Production Engineer 40

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Sanofi, Empowering Life. For further information, please visit www.sanofi.com.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. This press release contains “forward-looking statements” of. Empowering Life.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

APRIL 18, 2022

While the data did not meet its endpoints, the program has contributed to the scientific understanding of antibody-based treatment to address the virus and highlighted the broader therapeutic value and importance of plasma to treat rare diseases.

Vaccination 52

Vaccination Vaccine Manufacturing Clinical Trials 52